{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:27:13Z","timestamp":1758040033111,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1999,7,1]],"date-time":"1999-07-01T00:00:00Z","timestamp":930787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,7,1]],"date-time":"1999-07-01T00:00:00Z","timestamp":930787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[1999,7]]},"DOI":"10.1053\/hj.1999.v138.99080","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T09:55:56Z","timestamp":1103709356000},"page":"s39-s46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S","title":["Oral blockade of the platelet glycoprotein IIb\/IIIa receptor: Fact or fancy?"],"prefix":"10.1053","volume":"138","author":[{"given":"Dean J.","family":"Kereiakes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/hj.1999.v138.99080_BIB1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy: I, prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"Br Med J"},{"key":"10.1053\/hj.1999.v138.99080_BIB2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1161\/01.CIR.91.7.1929","article-title":"Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes","volume":"91","author":"Granger","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0002-8703(96)90520-7","article-title":"Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty","volume":"131","author":"Smith","year":"1996","journal-title":"Am Heart J"},{"key":"10.1053\/hj.1999.v138.99080_BIB4","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/01.CIR.93.5.870","article-title":"Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial","volume":"93","author":"Granger","year":"1996","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB5","first-page":"I-431","article-title":"Variable inhibition of coagulation activity during and after heparin infusion in patients with unstable coronary artery disease [abstract]","volume":"94","author":"Oldgren","year":"1996","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB6","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.99080_BIB7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.99080_BIB8","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: the IMPACT-II trial","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.99080_BIB9","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.99080_BIB10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.99080_BIB11","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.CIR.96.1.76","article-title":"First chronic platelet glycoprotein IIb\/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions","volume":"96","author":"Simpfendorfer","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/01.CIR.97.4.340","article-title":"Randomized trial of an oral platelet glycoprotein IIb\/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial","volume":"97","author":"Cannon","year":"1998","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/01.CIR.94.5.906","article-title":"Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: administration for complex coronary intervention","volume":"94","author":"Kereiakes","year":"1996","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/01.CIR.96.4.1117","article-title":"Sustained platelet glycoprotein IIb\/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment","volume":"96","author":"Kereiakes","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB16","first-page":"I-385","article-title":"Safety and efficacy of prolonged platelet GP IIb\/IIIa blockade with xemilofiban: final results of the ORBIT trial [abstract]","volume":"96","author":"Kereiakes","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB17","first-page":"I-385","article-title":"Sustained platelet gp IIb\/IIIa blockade with oral xemilofiban: final results of the ORBIT trial [abstract]","volume":"96","author":"Kereiakes","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/01.CIR.98.13.1268","article-title":"Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb\/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial","volume":"98","author":"Kereiakes","year":"1998","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB19","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","article-title":"Aspirin as an antiplatelet drug","volume":"330","author":"Patrono","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.99080_BIB20","unstructured":"Searle study NG7-96-ST-045 (Xemilofiban) protocol #NG79502045; 1999. (Data on file at G.D. Searle.)"},{"year":"1998","author":"Oliver","key":"10.1053\/hj.1999.v138.99080_BIB21"},{"year":"1997","author":"Catella-Lawson","key":"10.1053\/hj.1999.v138.99080_BIB22"},{"key":"10.1053\/hj.1999.v138.99080_BIB23","first-page":"3828","article-title":"Monitoring platelet GP IIb\/IIIa antagonist therapy","volume":"96","author":"Coller","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB24","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1161\/01.CIR.96.11.3860","article-title":"Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb\/IIIa therapy","volume":"96","author":"Mascelli","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.99080_BIB25","first-page":"I-251","article-title":"Chronic oral glycoprotein IIb\/ IIIa antagonism with unstable coronary artery disease [abstract]","volume":"98","author":"Catella-Lawson","year":"1998","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870399004469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870399004469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:11:34Z","timestamp":1757567494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870399004469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,7]]}},"alternative-id":["S0002870399004469"],"URL":"https:\/\/doi.org\/10.1053\/hj.1999.v138.99080","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[1999,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral blockade of the platelet glycoprotein IIb\/IIIa receptor: Fact or fancy?","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/hj.1999.v138.99080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}